183 related articles for article (PubMed ID: 36443540)
21. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
Climent MA; Font A; Durán I; Puente J; José Méndez-Vidal M; Sáez MI; Santander Lobera C; Ángel Arranz Arija J; González-Del-Alba A; Sánchez-Hernandez A; Juan Fita MJ; Esteban E; Alonso-Gordoa T; Mellado Gonzalez B; Maroto P; Lázaro-Quintela M; Cassinello-Espinosa J; Pérez-Valderrama B; Garcias C; Castellano D
Eur J Cancer; 2022 Nov; 175():110-119. PubMed ID: 36099670
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
23. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy].
Merseburger AS; Rüssel C; Belz H; Spiegelhalder P; Feyerabend S; Tran N; Kruetzfeldt K; Baurecht W; Bögemann M
Aktuelle Urol; 2020 Dec; 51(6):562-571. PubMed ID: 32268436
[TBL] [Abstract][Full Text] [Related]
24. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
25. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
26. Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
Takahara K; Naiki T; Ito T; Nakane K; Koie T; Yasui T; Miyake H; Shiroki R
Int J Urol; 2022 Mar; 29(3):229-234. PubMed ID: 34863085
[TBL] [Abstract][Full Text] [Related]
27. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
[TBL] [Abstract][Full Text] [Related]
30. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
[TBL] [Abstract][Full Text] [Related]
31. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
Duarte C; Jimeno A; Kessler ER
Drugs Today (Barc); 2019 Jan; 55(1):5-15. PubMed ID: 30740608
[TBL] [Abstract][Full Text] [Related]
32. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
33. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
34. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
[TBL] [Abstract][Full Text] [Related]
35. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
36. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
37. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
Ternov KK; Sønksen J; Fode M; Lindberg H; Kistorp C; Bisbjerg R; Faber J; Klausen TW; Palapattu G; Østergren PB
Eur J Cancer; 2022 Aug; 171():75-84. PubMed ID: 35709600
[TBL] [Abstract][Full Text] [Related]
38. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
39. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
Manceau C; Mourey L; Pouessel D; Ploussard G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
[TBL] [Abstract][Full Text] [Related]
40. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
